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Abstract
Purpose Polyglandular autoimmune syndromes (PAS) are complex, heterogeneous disorders in which various autoimmune 
diseases can occur, affecting both endocrine and non-endocrine organs. In this meta-analysis, the prevalence of associated 
autoimmune disorders was investigated in PAS II and III.
Methods A comprehensive search in MEDLINE and Embase databases identified 479 studies with the keywords of PAS II 
and PAS III. 18 records containing a total of 1312 patients fulfilled our inclusion criteria (original studies reporting at least 
10 cases and containing the combination of other autoimmune disorders) and were selected for further analysis. A meta-
analysis of prevalence was performed using the random-effects model with the calculation of 95% confidence intervals (CI). 
Results of each meta-analysis were displayed graphically using forest plots.
Results Distinction between PAS II and PAS III was made in 842 cases, of which 177 and 665 were PAS II and III (21.1 vs 
78.9%), respectively. The prevalence of Hashimoto’s thyroiditis was significantly higher than that of Graves’s disease (39% 
[95% CI 17–65%] vs. 4% [95% CI 0–10%], respectively; p = 0.001). In PAS II, Addison’s disease (AD) coexisted with AITDs, 
T1DM or the combination of these conditions in 65, 18 and 10% of cases, respectively. In addition, one other endocrine and 
five non-endocrine organ-specific autoimmune disorders were reported. In PAS III, two other autoimmune endocrinopathies, 
six non-endocrine organ-specific, and four systemic autoimmune disorders were found in combination with AITDs.
Conclusions AITDs, T1DM and AD are the most common combinations in PAS, thus screening for these conditions seems 
to be reasonable.
Keywords Polyglandular autoimmune syndrome · Addison’s disease · Autoimmune thyroid disease · Diabetes mellitus · 
Meta-analysis
Introduction
Autoimmune polyglandular syndromes (PAS) are complex, 
heterogeneous disorders in which various autoimmune dis-
eases can occur, affecting both endocrine and non-endocrine 
organs. The diagnosis of PAS can be established if at least 
two organs are damaged by the autoimmune process [1]. 
PAS can be further divided into four subgroups based on the 
affected organs [2]. PAS I or early-onset PAS develops as a 
result of the mutation of the autoimmune regulator (AIRE) 
gene and is characterized by the presence of Addison’s dis-
ease (AD), mucocutaneous candidiasis and hypoparathy-
roidism [2]. PAS II is defined by the presence of AD and 
autoimmune thyroid diseases (AITDs) and/or type 1 diabetes 
mellitus (T1DM) [2]. In PAS III, AITD can co-occur with 
any autoimmune disorder, but not with AD [2–5]. Patients 
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who cannot be included in the previous three subgroups 
are classified as PAS IV [2–6]. Further classifications can 
also be found in the literature. Authors Frommer et al. and 
Kahaly et al. proposed a distinction between juvenile (I) and 
adult (II–IV) forms of PAS [1, 7]. Their definition of PAS 
III is also different, as they consider the presence of both 
AITD and T1DM (without AD) obligatory for this group 
[1, 7]. Most studies analyzed in our paper divided PAS III 
into several further subgroups, which are presented in detail 
in Table 1.
The typical characteristics of PAS are the lymphocytic 
infiltration of endocrine and non-endocrine organs, the pres-
ence of autoantibodies against the affected organs and the 
defects of cellular and humoral immune responses [4, 8, 9]. 
In PAS II and III, the main affected genes are the HLA, 
CTLA-4 and PTPN-22 genes [10]. Beyond the autoimmune 
disorders which are obligatory for the diagnosis, both PAS 
II and III can be associated with a wide variety of other 
autoimmune conditions. Autoimmune disorders of the endo-
crine glands such as AITDs, T1DM, AD, premature ovarian 
failure (POF), hypoparathyroidism or hypophysitis may be 
combined with non-endocrine organ-specific autoimmune 
disorders including vitiligo, alopecia, inflammatory bowel 
diseases (IBD), coeliac disease, autoimmune hepatitis, 
pernicious anemia, haemolytic anemia, multiple sclerosis 
or myasthenia gravis. Furthermore, systemic autoimmune 
Table 1  Definitions of polyglandular autoimmune syndrome type II and type III across the studies included
a No definition given in the study, we characterized the subgroups, as follows: polyglandular autoimmune syndrome type II: Addison’s disease 
and autoimmune thyroid disease and/or type I diabetes mellitus; polyglandular autoimmune syndrome type III: autoimmune thyroid disorders 
and other autoimmune diseases except Addison’s disease
AD Addison’s disease, AITD autoimmune thyroid disorders, PAS polyglandular autoimmune syndrome, T1DM type 1 diabetes mellitus
Article Polyglandular autoimmune syndrome type II Polyglandular autoimmune syndrome type III
Abrar-Ahmad [29] AD and AITD and/or T1DM and other auto-
immunities
The absence of adrenal insufficiency
III/a-AITD and T1DM and sarcoidosis or 
coeliac disease
III/b-AITD and pernicious anemia
III/c-AITD and vitiligo or alopecia
Ben-Skowronek et al. [27] AD and AITD and/or T1DM AITD plus other endocrinopathy except for AD
III/A-AITD and T1DM
III/B-AITD and pernicious anemia
III/c-AITD and vitiligo and/or alopecia and/or 
other organ-specific autoimmune diseases
Betterle et al. [31] AD and AITD and/or T1DM AITD and other autoimmune diseases excluding 
AD and/or hypoparathyroidism
Cruz et al. [20] AD and AITD and/or T1DM PAS type III differs from type II by the absence 
of AD
Dittmar and Kahaly [21] AD and AITD and/or T1DM Apart from the absence of AD, there is no 
clinical difference between PAS type II and 
type III
Horie et al. [23] a AITD and T1DM
Papadopoulos and Hallengren [25] AD and AITD and/or T1DM without hypopar-
athyroidism or chronic mucocutaneous 
candidiasis
a
Papadopoulos et al. [26] AD and AITD and/or T1DM AITD and T1DM and/or pernicious anemia 
and/or vitiligo/alopecia
Piatkowska and Szalecki [22] a AITD and at least one of autoimmune disease: 
T1DM, pernicious anemia, vitiligo, alopecia 
areata, coeliac disease, hypogonadism, myas-
thenia gravis and others excluding AD
Sastre-Garriga [28] AD and AITD and/or T1DM for primary 
criteria, secondary criteria can be gonadal 
failure, vitiligo, alopecia and pernicious 
anemia
a
Storz et al. [35] AD and AITD and/or T1DM AD excluded
Choudhuri et al. [19], Handa and Dogra  [34], 
Karagüzel et al. [32], Karavanaki et al. [33], 
Kondonouri et al. [26], Renzullo et al. [3], 
Teufel et al. [30]
a a
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disorders such as rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), psoriasis, systemic sclerosis and poly-
myositis could also be comorbidities [11]. The prevalence of 
autoimmune disorders has been showing an increasing trend 
for the last decade [12]. Unfortunately, these disorders are 
usually considered to be isolated diseases instead of comor-
bidities, which could be one reason for the low number of 
publications that includes data from larger patient popula-
tions in the literature. Another difficulty is that some review 
articles present data about potential co-associated disorders 
without defining them as PAS, i.e. the work of Fallahi et al., 
who demonstrated that several endocrine, non-endocrine 
organ-specific and systemic autoimmune diseases are more 
frequent in AITD patients [13]. It is also important to note 
that the prevalence and type of co-associated autoimmuni-
ties can be remarkably different in pediatric and adult AITD 
patients. Furthermore, certain autoimmune disorders such as 
T1DM and juvenile idiopathic arthritis (JIA) often present in 
childhood, whereas co-associated AITD might appear later 
during adulthood, altering both the initial diagnosis and the 
prevalence of PAS in childhood [14].
The aims of this meta-analysis were to collect studies 
systematically to characterize the prevalence of autoimmune 
diseases other than the obligatory manifestations of PAS II 
and PAS III and to investigate the characteristics of PAS 
II and PAS III in relation to gender and age. It is not clear 
yet which comorbidities can appear with AD, therefore we 
also aimed to identify both the autoimmune diseases which 
co-occur with AD and those disorders which do not. Here, 
we present a systematic review and the first meta-analysis 
to verify the combinations of autoimmune disorders in PAS 
II and III.
Methods
This meta-analysis was reported in accordance with the rec-
ommendations of the Preferred Reporting Items for Systemic 
Reviews and Meta-Analyses (PRISMA) statement [15] and 
was registered in PROSPERO with registration number 
CRD42019126826.
Search strategy
We searched the following electronic bibliographic data-
bases: MEDLINE (via PubMed) and EMBASE, and used 
only ‘human’ filter. There was no language restriction. The 
search was completed by 5th November 2018, with the fol-
lowing keywords: “autoimmune polyglandular syndrome”, 
“autoimmune polyendocrinopathies”, “autoimmune polyg-
landular syndrome type II” and “autoimmune polyglandu-
lar syndrome type III”. The EndNote software (version: X 
7.0.2., Clarivate Analytics, Philadelphia, PA, USA) was used 
to manage all references to remove duplicates and facilitate 
the selection process.
Inclusion and exclusion criteria
For inclusion, publications had to demonstrate that (1) the 
study focused on patients with two or more autoimmune 
disorders of endocrine and non-endocrine organs and (2) 
the study showed data of at least 10 cases. Publications were 
excluded (1) in the case of overlapping study populations and 
(2) if the study focused on patients only with autoimmune 
disorders of non-endocrine organs. Review articles were also 
excluded. The records were independently screened by two 
investigators against the inclusion and exclusion criteria.
Data extraction
A standardized form of numeric data was independently 
extracted by two investigators and manually populated into 
a purpose-designed Excel 2016 sheet (Office 365, Microsoft, 
Redmond, WA, USA) containing the following information: 
year of publication, type of study, participating centers, 
number of patients included and diagnosed with PAS, aver-
age age of the patients, sex, main disorders (AD, AITDs, 
T1DM, POF, vitiligo, alopecia, coeliac disease, autoimmune 
hepatitis, pernicious anemia, autoimmune bowel disease, 
haemolytic anemia, SLE, psoriasis, Sjögren’s syndrome, 
RA, myasthenia gravis, multiple sclerosis, hypoparathy-
roidism, hypophysitis) and their combinations. The authors 
of the original studies were contacted to obtain missing 
information.
Statistical analysis
The methods recommended by the working group of the 
Cochrane Collaboration [16] were used for the synthesis of 
data. Event rates (in percentage distribution) were calcu-
lated for dichotomous outcomes. Random-effects model was 
applied for all analysis with the DerSimonian–Laird estima-
tion [17]. Statistical heterogeneity was analyzed using the 
I2 and the χ2 tests to gain probability values; p < 0.1 was 
defined to indicate significant heterogeneity. Statistical 
analyses were performed with Stata 15 (Stata Corporation, 
College Station, TX, USA).
Assessment of the quality of the included studies
Two review authors independently assessed the quality 
of the included studies as recommended by Murad et al. 
[18] (Supplementary Table 1). Disagreements between the 
review authors over the quality were resolved by discussion, 
with the involvement of a third review author where it was 
necessary.




After the comprehensive search in MEDLINE and Embase, 
479 records were identified. After removing duplicates, we 
reviewed the remaining 454 records against the eligibility 
criteria, and excluding case reports, 18 articles containing 
a total of 1312 patients (10–254/papers) were selected for 
further analysis. Our PRISMA flow chart of the selection 
process is shown in Fig. 1. Caucasian, Asian and Hispanic 
ethnicities were included. Characteristics of the studies 
included in PAS II and III are summarized in Supplemen-
tary table 2.
Characteristics of the patients
According to 9 studies which mentioned the age of the 
patients, the overall mean age of the PAS patients was 
34.7 years (95% CI: 22.75–46.64 years) [3, 19–26] (Fig. 2). 
Females were more often affected by PAS than males (75% 
[95% CI 68–81%] vs. 25% [95% CI = 19–32%], p < 0.001), 
according to the 12 articles containing the female–male ratio 
[3, 19–28] (Fig. 3). Distinction between PAS II and PAS III 
was made in 842 cases, 177 and 665 of which were PAS II 
and III (21.1% vs 78.9%), respectively [3, 11, 19–24, 26–36]. 
There was a significant difference between these groups 
according to the pooled effect sizes (9% (95% CI 0–26%) vs 
43% (95% CI 21–67%) (Fig. 4). The most prevalent autoim-
mune endocrinopathies were AITDs, T1DM and AD (970, 
697 and 174 cases, respectively).
Prevalence of other autoimmune disorders 
beyond the obligatory manifestations of PAS II 
and PAS III
In PAS II, AD coexisted with AITDs, T1DM or the combi-
nation of these conditions in 114, 32 and 18 cases, respec-
tively. In addition, one other endocrine (POF) and five non-
endocrine organ-specific autoimmune disorders (pernicious 
anemia, alopecia, coeliac disease, multiple sclerosis and 
vitiligo) were reported.
Fig. 1  PRISMA flow diagram
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In PAS III, two other autoimmune endocrinopathies (POF 
and T1DM), six non-endocrine organ-specific (vitiligo, auto-
immune hepatitis, pernicious anemia, myasthenia gravis, 
coeliac disease and alopecia) and four systemic autoimmune 
disorders (RA, SLE, Sjögren’s syndrome and psoriasis) were 
detected in combination with AITDs [3, 11, 19–24, 26–35].
The number of associated autoimmune disorders 
in PAS II and III
The patients were separated into three subgroups as fol-
lows: patients with a combination of two, three and more 
than three disorders. The proportion of dual combinations 
among PAS III patients was significantly higher than in PAS 
II patients [476 (75.7%) vs 152 (24.3%), p < 0.001]. There 
was no significant difference in the frequencies of triple 
combinations between the PAS II and PAS III patients (33 
(44.6%) vs 41 (55.4%), p = 0.739), while patients with more 
than three autoimmune disorders were only found in PAS II 
(5 (100.0%) vs 0 (0.0%), p = 0.001) (Fig. 5).
Combinations of autoimmune disorders with AD
Among PAS II, 174 combinations were diagnosed. AD 
occurred in dual combinations in 83.9% of the PAS II 
patients. Among these patients, only AITD and T1DM were 
found in dual combinations in 114 and 32 cases, respec-
tively. Triple combinations were diagnosed in 18 cases 
(10.3%), only 13 of which (7.5%) showed the classical triad 
of PAS II (AD, AITD and T1DM). Beyond these conditions, 
alopecia, POF, coeliac disease, pernicious anemia, multiple 
sclerosis and vitiligo developed with AD.
Autoimmune bowel diseases, autoimmune hepatitis, 
hypoparathyroidism, hypophysitis, myasthenia gravis, pso-
riasis, rheumatoid arthritis, Sjögren’s syndrome and SLE 
were not reported in combination with AD. Interestingly, 
systemic autoimmune disorders coexisted with AD only if 
four or five autoimmune disorders developed.
Discussion
PAS is a complex and heterogeneous disorder. The fact that 
these conditions are so rare and that the number of variations 
is so high make the use of evidence-based approach dif-
ficult [1, 7]. The screening and diagnostic protocol of these 
patients is a hard task for clinicians [34]. To our knowledge, 
this is the first meta-analysis in the field of PAS.
In PAS II, AD is present in 100% of the cases, AITDs 
in 69–82% and T1DM in 30–52% of the patients [36]. No 
analysis of the other coexisting autoimmune disorders was 
previously available. The aim of this meta-analysis was to 
identify the main characteristics of PAS patients according 
to age, gender and combination of autoimmune disorders to 
develop relevant diagnostic and screening protocols. PAS II 
frequently appears later than PAS I, mostly in young adult-
hood [37]. The mean age of the PAS patients at the time of 
diagnosis in our work was 34.7 years, which is unexpectedly 
high [38, 39]. It is well known that PAS are more common in 
females [1, 12] and this was confirmed by our study as well. 
Fig. 2  Mean age of polyglan-
dular autoimmune syndrome 
patients; the pooled mean age of 
polyglandular autoimmune syn-
drome patients was 34.7 years
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As opposed to the common belief, PAS III was more preva-
lent than PAS II [25]. This is due to the much higher preva-
lence of AITDs in comparison with AD, which is a diag-
nostic criteria for PAS II [12]. In fact, AITDs are the most 
common autoimmune endocrinopathies in combination with 
other autoimmune conditions [13]. According to literature 
data, dual combinations in PAS II are more common than the 
classical triad of AD, AITDs and T1DM, which appears true 
only for approximately 10–20% of cases [40]. According 
to our results, AD occurred in dual combinations in 83.9% 
of the PAS II patients, while the proportion of the triple 
combinations was 10.3%. The combination of AD, AITD 
and T1DM was diagnosed in 7.5% of PAS II patients. More 
than three autoimmune manifestations are more common in 
patients who have Addison’s disease [37]. Unfortunately, 
the categorization of the patients suffering from two or more 
autoimmune disorders in the PAS subgroups is not a clear 
task for the clinicians [1, 12]. These patients are receiving 
medications and therapies for their disorders separately and 
their conditions are not managed as a part of a complex dis-
ease. This may be the reason why only 18 articles fulfilled 
the inclusion criteria in this meta-analysis.
There are some limitations of our meta-analysis. We 
found case studies in a large number, while case series—
studies analyzing larger populations—were found in a lim-
ited number. The data found in case studies could not be 
used for statistical analyses. In the future, the classification 
of PAS patients suffering from two or more autoimmune 
Fig. 3  Gender distribution of polyglandular autoimmune syndrome patients; females were more often affected by polyglandular autoimmune 
syndrome than males
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disorders is important to better understand the epidemio-
logical data and the possible combinations of autoimmune 
disorders. The prevalence of autoimmune thyroid diseases 
is 40–200 times higher than that of Addison’s disease in 
the general population and in association studies, the refer-
ence disorder must be the most frequent. Development of 
consecutive registries for autoimmune thyroid disorders 
and other autoimmune endocrinopathies seems to be 
essential to estimate the real prevalence of co-associations.
PAS II and PAS III are both due to polymorphisms in 
the HLA DQ/DR regions [10]. PAS II has been found to be 
strongly associated with HLA haplotypes with DR3/DQ2 
and DR4/DQ8 and with DRB1*0404 [10]. Identification of 
the affected regions may be useful to estimate the risk of 
Fig. 4  Distribution of patients between polyglandular autoimmune syndrome type II and III; the proportion of polyglandular autoimmune syn-
drome type III patients was significantly higher than that of polyglandular autoimmune syndrome type II patients
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PAS. Circulating organ- and cell-specific autoantibodies can 
be detected in patients with the syndrome [41]. However, 
it is difficult and expensive to search for all these markers 
during the follow-up period. Based on risk assessment, 
the screening of high-risk individuals would be possible. 
The screening process is further complicated by the late 
manifestation of the second autoimmune disorder; decades 
may elapse between two autoimmune manifestations [42]. 
Detailed data are not available in the literature, few reports 
found that the shortest interval may be between AD and 
AITD, the longest between T1DM or vitiligo and AITDs 
[42]. There are some studies about the prevalence of com-
bined autoimmunities among children and adults [14]. Asso-
ciation of autoimmune disorders is more common in adult 
patients; however, many autoimmune diseases can develop 
in childhood [14].
In conclusion, our meta-analysis clearly confirmed that 
the association of various other forms of autoimmune disor-
ders which are not the obligatory components of PAS is not 
uncommon. However, AITDs, T1DM and AD are the most 
frequent combinations occurring in PAS, thus screening for 
these conditions seems to be reasonable. The development of 
relevant diagnostic and screening protocols to identify these 
patients timely is warranted.
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